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Summary: The analytical, intra- and inter-individual components of biological variation were estimated for protein
C, protein S and antithrombin over a period of 6 weeks in a cohort of 17 apparently healthy subjects. Expressed as
percentage activity (protein C and antithrombin) and as percentage concentration in normal human plasma (protein
S), the mean values for men and women show no significant differences (p > 0.05) for any of the analytes studied.
Calculated analytical goals (CV, %) for precision required for optimal patient care are: protein C, 2.9; protein S,
2.9 and antithrombin 2.7. A single numerical index, called "index of fiduciality", was also calculated to demonstrate
that the analytical performance of our method was satisfactory. The generally applicable differences (% activity or
% concentration) required for two results to be significantly different (p ^  0.05) were calculated as: protein C, 17;
protein S, 16 and antithrombin, 16. The usefulness of critical differences as guidelines for the interpretation of
changes in serial results was investigated using an "index of heterogeneity" of intra-individual variation.
The marked degree of individuality demonstrated for all the quantities indicates that, if conventional population-
based ranges are used uncritically, major changes in analyte concentration may not be correctly identified for some
patients, because observed values continue to lie within the reference range. The utility of conventional population-
based reference intervals was determined by calculating a single numerical index, called "index of individuality".
For protein C, protein S and antithrombin we found that five of a patient's specimens are required to achieve a
95% chance that the mean is within ± 5% of the true value.
Introduction six specimens from each subject over a period of
Data on the biological variation of analyte concentra-
tions have many valuable uses in clinical chemistry (1),
including setting desirable performance standards for
 Materials and Methods
imprecision (2), determining the true significance of
changes in serial results from a single patient (3) and SubJects
assessing the usefulness of conventional population- Seventeen apparently healthy hospital staff members (nine females
based reference ranees (4) and eight men' ages 21 to 52 vears)' informed ab°ut the objective
° ^ '' of the study, were recruited. They were non-smokers, and had taken
Although many data are available on the biological vari- no me?'f*οη '"the ^ f Uf ^° ίΤ*5' ^  maintained *eirβ J &
 usual lifestyles throughout. None of the women was pregnant or
ation of analytes in serum or plasma (5—7), the true using oral contraceptives,
biological variation of the three naturally occurring anti-
coagulant proteins, protein C, protein S and antithrom- Specimen collection and handling
bin (8-9), has not been investigated in depth. A previ- preparation of the subjects before blood coiiection was carefully
ous Study on the biological variation of antithrombin has controlled, and blood collection was performed in standardized
been reported (3), but in that article the discussion was conditions to minimize sources of preanalytical variation. After an
,. . , , . - J - - J 1 ·· j · · ι i-r- overnight fast, a blood specimen was taken with minimal venous
limited to the mtra-mdividual variation and critical dif-
 Occlusion5 between 8 ^  10 a. m. to avoid the influence of circa-
ference. dian variation on the plasma concentrations of the studied quanti-
ties. Six consecutive blood samples were taken weekly from each
Since the values of these quantities are widely used in subject. All samples were drawn by the same phlebotomist from
clinical decision making, we believe that their biological subjects in a supine position. The first 4 ml were discarded, and
. . ι υ ι · j venous blood was then sampled into evacuated tubes containing
variation should be examined.
 129 mmol/1 ^souum citrate (Venoject VT-050SCBS, Terumo-
,,r Al ,, j ι · ι · ι · ι · · · Europe, Leuven, Belgium). Plasma was obtained by centrifugationWe therefore assessed their biological variation m a
 (2000gj ^  4 oc for 10 min) ^  stored at _80 oc ^  ^ ^
cohort of 17 apparently healthy subjects, collecting At the end of 6 weeks, all frozen samples were transferred into a
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water bath at 37 °C for 15 minutes and then handled at room tem-
perature.
Analytical techniques
The analytical protocol was designed to minimize analytical vari-
ance both within and between batches of analyses. Each set of
specimens from an individual was assayed in duplicate, in no spe-
cific sequence, within the same analytical batch. Single lots of rea-
gents, standards and quality-control materials were used throughout,
and analyses were performed by a single operator. Comparability
between runs was ensured by rigorous quality control. The activi-
ties of protein C and antithrombin were measured on a Hitachi 911
analyzer using a synthetic chromogenic substrate (antithrombin and
Stachrom protein C, Boehringer Mannheim, Mannheim, Germany),
while quantitative determination of protein S concentration was
performed using a microlatex particle-mediated immunoassay
(Liatest protein S, Boehringer Mannheim, Mannheim, Germany).
Statistical analysis of data
The detailed approach advocated by Fräser & Harris (1) was fol-
lowed. After exclusion of outliers, nested analysis of variance (AN-
OVA) was applied. The total variance was divided into the compo-
nents attributable to analytical, intra- and inter-individual variation.
Since, in assay procedures, quality control materials may not be-
have in the same way as specimens from patients (10), we calcu-
lated analytical variance from the results of duplicate analyses of
each specimen. We used only the first of each duplicate result to
calculate the average intra-individual variance and the inter-indivi-
dual variance. Student's unpaired t-test was used to assess whether
the means for men and women were different.
Results and Discussion
Analytical results
The mean values for men and women showed no signifi-
cant difference (p < 0.05) for each of the analytes
studied (fig. 1). The data generated were therefore
treated as a single set of data.
Table 1 shows the mean values and estimated analytical
(CVA), intra- (CVG) and inter-individual (CVI) varia-
tion as coefficients of variation of protein C, and
antithrombin percentage activity and protein S percen-
tage concentration in normal human plasma.
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Fig. 1 Means and ranges for protein C, protein S and antithrom-
bin in sera from 17 healthy subjects. 1 — 8: male; 9—17: female.
The data in the table 1 were used to:
— derive analytical goals for each quantity analysed,
— determine the changes required in serial results,
termed critical difference (3), before significance can
be claimed,
— assess the usefulness of conventional population-
based reference values,
— estimate the number of specimens required to pro-
duce a more precise estimate of the homeostatic set
point of an individual.
Analytical goals
Stipulated standards of performance are necessary for
the objective analysis of the data generated during the
analytical investigation. It is widely accepted that ana-
lytical goals, the standards of analytical performance re-
quired to provide optimal patient care, are best derived
from data on biological variation (11). Goals for im-
precision were derived as 1/2CVI (2). The goals for im-
precision for all quantities were met in this study, as
shown in table 2.
A single numerical index, called "index of fiduciality",
was also suggested to demonstrate whether a method
met the analytical goals or not (12). It is calculated as
the total analytical error achieved (CVA) divided by the
analytical goal. If this index is < 1, then the analytical
goal is met. The calculated indices of fiduciality, de-
Tab. 1 Mean values, and estimated average analytical (CVA), in-
tra-individual (CVI) and inter-individual (CVG) variation in heal-
thy subjects for protein C, protein S and antithrombin.
Analyte Mean3 CVA CVI CVG
Protein C
Protein S
Antithrombin
106.8
117.6
119.1
2.1
2.0
1.8
5.8
5.8
5.5
55.2
63.4
25.2
a
 Mean values are expressed as percentage activity for protein C
and antithrombin and percentage concentration in normal human
plasma for protein S.
Tab. 2 Estimated indices of individuality, heterogeneity, fiducial-
ity, analytical goals for precision, critical differences between serial
results and required numbers of specimen collections to produce a
more precise estimate of the homeostatic set point in healthy sub-
jects for protein C, protein S and antithrombin.
Protein C Protein S
Index of individuality
Index of heterogenity
Index of fiduciality
Analytical goal, CV (%)
Critial difference (%)
No. of specimens required
0.1
0.65
0.72
2.9
17
5.8
0.1
0.64
0.68
2.9
16
5.7
Anti-
thrombin
0.2
0.64
0.66
2.7
16
5.1
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tailed in table 2, provide evidence that the analytical
performance of our method was satisfactory.
Critical difference
The results of biochemical tests are often used in moni-
toring patients. It is therefore important to know the
magnitude of the changes in serial results from an indi-
vidual that amount to statistically significant differences.
Such changes may be due not only to improvement or
deterioration of the patient but also to analytical im-
precision and intra-individual biological variation.
Therefore, for a change to be significant, it must exceed
the critical difference, which can be defined as the total
variation required in serial results from an individual
before significance can be claimed. For p < 0.05 the
critical difference can be calculated as 2.77(CVA2
+ CVI2)1/2 (3). The calculated critical differences for
protein C, protein S and antithrombin are listed in
table 2.
Use of the average CVI to calculate critical differences
is truly valid only if all subjects have the same CVI.
This was investigated using an "index of heterogeneity"
of intra-individual variation. This index is defined as the
ratio of the observed CV of a set of individual variances
(CVA2 + CVI2)172 to the theoretical CV if no hetero-
geneity existed, namely [2/(n—1)]1/2, where n is the
average number of observations per subject (13). If there
were no heterogeneity of intra-individual variances, this
ratio would be 1.00. When the index differs from unity
by more than 2 SD, defined by 2/(2n)1/2, then significant
heterogeneity exists. The calculated indices of hetero-
geneity for the analytes investigated are described in ta-
ble 2. Since no index exceeds 1.00 by more than 2 SD,
we believe that the critical differences detailed here are
useful in clinical practice as guidelines in the interpreta-
tion of changes in serial results.
Our data on the critical difference and the CVI of
antithrombin monitored over a six weeks period appear
to be of the same order as those observed over six
months by Costongs et al. (i.e., critical difference,
19.6%; CVI, 6.6%) (3). In Costongs' work the intra-
individual variations and the critical differences of 9 co-
agulation quantities were investigated during short-term
(within-one-day) and long-term (six months) periods.
The antithrombin long-term CVI was found to be much
smaller than the short-term one (16.3%), highlighting
the fact that variations over the day should therefore be
interpreted carefully.
Usefulness of conventional population-based
reference values
Reference intervals are of particular importance when a
test is used for screening or in making an initial diagno-
sis, when no previous data are available on an indivi-
dual. The dispersion of conventional reference intervals
is due to a composite of analytical, intra- and inter-indi-
vidual variation. Conventional population-based refer-
ence values are of use only when the intra-individual
variability exceeds the inter-individual variability. The
ratio of the intra- to inter-individual biological variation,
known as the "index of individuality" provides informa-
tion on the utility of conventional population-based ref-
erence intervals (14). When this index is less than 0.6,
reference values are of limited utility, but when it is
more than 1.4, such values are of considerable use. Table
2 shows the indices of individuality for protein C, pro-
tein S and antithrombin. For all the quantities, the index
is < 0.6. This high degree of individuality means that
subjects could have values that are very unusual for
them but still lie within the conventional reference in-
terval. Thus, the analytes examined in this study, al-
though commonly assayed in clinical chemistry
laboratories, will be of little use in the diagnosis of early
or latent disease, or as general population-screening
tests.
Number of specimens required
Since many analytes show considerable intra-individual
variation, analyses of multiple specimens will produce a
more precise estimate of the homeostatic set point. The
required number of specimen collections needed to esti-
mate the mean to within a desired precision, may be
calculated from a rearrangement of the usual formula
for the standard error of the mean:
n = [Z(CVA2 + CVI2)1/2/D]2,
where n is the number of specimens required, Z the
number of standard deviates required for a stated prob-
ability under the normal curve, and D is the desired per-
centage closeness to the homeostatic set point (1).
For protein C, protein S and antithrombin we found that
five of a patient's specimens are required to achieve a
95% chance that the mean is within ± 5% of the true
value.
Conclusions
Data on analytical, intra- and inter-individual variation
support the following conclusion:
- analytical goals derived from data on biological
variation for protein C, protein S and antithrombin
indicate that the standard of analytical performance
achieved at present may be adequate for ideal pa-
tient care;
— the intra-individual variation exhibited by protein C,
protein S and antithrombin means that, even when ana-
lytical goals for precision are met, relatively large differ-
ences (i.e., 16—17%) between sequential results are re-
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quired before two values can be said to be significantly
different;
— population-based reference ranges are of limited
value for the interpretation of results of measurements
of protein C, protein S and antithrombin, because of the
high degree of individuality for these quantities in
plasma. Thus assays for protein C, protein S and
antithrombin in plasma are likely to be useful in moni-
toring individuals but not in detecting disease with the
desired nosological sensitivity.
- five specimens should be collected for protein C,
protein S and antithrombin to estimate the homeostatic
set point of an individual.
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